Related Experiment Video
Updated: Jan 17, 2026
08:39
Stereotaxic Injection of a Viral Vector for Conditional Gene Manipulation in the Mouse Spinal Cord
Published on: March 18, 2013
31.8K
AAV vectors: an emerging strategy for chronic pain management
Romina Nassini1, Martina Chieca1, Matilde Marini1
1Department of Health Science, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy; Department of Health Science, Viral Vectors, and Pharmacogenetics Core Laboratory (ASPIRE), University of Florence, Florence, Italy.
Trends in Molecular Medicine
|September 19, 2025
Summary
Adeno-associated virus (AAV) vectors show promise for gene therapy in chronic pain management. This review explores AAV
Area of Science:
- Gene Therapy
- Neuroscience
- Pain Management
Background:
- Chronic pain is a significant global health concern.
- Adeno-associated virus (AAV) vectors are emerging as a promising gene therapy tool.
- Preclinical evidence supports AAV's potential for managing various pain types.
Purpose of the Study:
- To systematically review AAV vector applications for chronic pain.
- To discuss preclinical and clinical findings in pain modulation.
- To analyze safety concerns associated with AAV therapy.
Main Methods:
- Systematic literature review of preclinical and clinical studies.
- Analysis of AAV vector targeting of molecular pain pathways.
- Evaluation of AAV innovations for neuropathic, inflammatory, and cancer pain.
Main Results:
- AAV vectors demonstrate potential for precise and sustained pain relief.
- Preclinical studies show efficacy in diverse pain models.
- Clinical data in osteoarthritis patients indicate pain modulation effects.
Conclusions:
- AAV gene therapy offers a novel strategy for chronic pain.
- Further research is needed to address safety and efficacy.
- AAV vectors hold significant therapeutic potential for pain management.
